» Articles » PMID: 17194904

Screening for Coronary Artery Disease After Mediastinal Irradiation for Hodgkin's Disease

Overview
Journal J Clin Oncol
Specialty Oncology
Date 2006 Dec 30
PMID 17194904
Citations 87
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Incidental cardiac irradiation during treatment of thoracic neoplasms has increased risks for subsequent acute myocardial infarction or sudden cardiac death. Identifying patients who have a high risk for a coronary event may decrease morbidity and mortality. The objective of this study was to evaluate whether stress imaging can identify severe, unsuspected coronary stenoses in patients who had prior mediastinal irradiation for Hodgkin's disease.

Patients And Methods: We enrolled 294 outpatients observed at a tertiary care cancer treatment center after mediastinal irradiation doses 35 Gy for Hodgkin's disease who had no known ischemic cardiac disease. Patients underwent stress echocardiography and radionuclide perfusion imaging at one stress session. Coronary angiography was performed at the discretion of the physician.

Results: Among the 294 participants, 63 (21.4%) had abnormal ventricular images at rest, suggesting prior myocardial injury. During stress testing, 42 patients (14%) developed perfusion defects (n = 26), impaired wall motion (n = 8), or both abnormalities (n = 8). Coronary angiography showed stenosis 50% in 22 patients (55%), less than 50% in nine patients (22.5%), and no stenosis in nine patients (22.5%). Screening led to bypass graft surgery in seven patients. Twenty-three patients developed coronary events during a median of 6.5 years of follow-up, with 10 acute myocardial infarctions (two fatal).

Conclusion: Stress-induced signs of ischemia and significant coronary artery disease are highly prevalent after mediastinal irradiation in young patients. Stress testing identifies asymptomatic individuals at high risk for acute myocardial infarction or sudden cardiac death.

Citing Articles

Long-term cardiac effects of modern treatment for Hodgkin's lymphoma.

Bjerring A, Smeland K, Stokke T, Haugaa K, Holte E, Rosner A Cardiooncology. 2024; 10(1):19.

PMID: 38576044 PMC: 10993441. DOI: 10.1186/s40959-024-00222-4.


Cardiovascular Outcomes Associated With Exposure To Radiation Therapy In Thoracic Malignancies: An Insight Study Using the National Inpatient Database.

Yilmaz M, Turk E, Sana M, Olafimihan A, Uygun I, Shoura S Cureus. 2023; 15(10):e47113.

PMID: 38021583 PMC: 10647132. DOI: 10.7759/cureus.47113.


Plaque Rupture in a Hodgkin Lymphoma Survivor without Cardiovascular Risk Factors 20 Years after Thoracic Radiotherapy: A Case Report.

Polomski E, de Graaf M, Jukema J, Antoni M J Cardiovasc Dev Dis. 2023; 10(8).

PMID: 37623337 PMC: 10456011. DOI: 10.3390/jcdd10080324.


Echocardiographic Findings in Asymptomatic Mediastinal Lymphoma Survivors Years after Treatment Termination.

Nabialek-Trojanowska I, Jankowska H, Slawinski G, Dabrowska-Kugacka A, Lewicka E J Clin Med. 2023; 12(10).

PMID: 37240533 PMC: 10219019. DOI: 10.3390/jcm12103427.


Radiotherapy-Induced Cardiotoxicity: The Role of Multimodality Cardiovascular Imaging.

Podlesnikar T, Berlot B, Dolenc J, Goricar K, Marinko T Front Cardiovasc Med. 2022; 9:887705.

PMID: 35966531 PMC: 9366112. DOI: 10.3389/fcvm.2022.887705.